Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians |
| |
| Authors: | Gallo Paul Maurer Willi |
| |
| Affiliation: | Novartis Pharmaceuticals, East Hanover, NJ, USA. |
| |
| Abstract: | This is a discussion of the following three papers appearing in this special issue on adaptive designs: 'FDA's critical path initiative: A perspective on contributions of biostatistics' by Robert T. O'Neill; 'A regulatory view on adaptive/flexible clinical trial design' by H. M. James Hung, Robert T. O'Neill, Sue-Jane Wang and John Lawrence; and 'Confirmatory clinical trials with an adaptive design' by Armin Koch. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
